{"id":820502,"date":"2025-03-03T08:35:57","date_gmt":"2025-03-03T13:35:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/"},"modified":"2025-03-03T08:35:57","modified_gmt":"2025-03-03T13:35:57","slug":"zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/","title":{"rendered":"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs <\/em>\n      <\/p>\n<p align=\"justify\">SAN DIEGO, March  03, 2025  (GLOBE NEWSWIRE) &#8212; Zentalis<sup>\u00ae<\/sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women\u2019s Cancer, to be held on March 14-17 in Seattle, Washington.<\/p>\n<p align=\"justify\">\n        <strong>Oral Presentation<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Abstract Title:<\/strong> Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes from Part 1b of the DENALI Study (GOG-3066)<\/li>\n<li style=\"text-align:justify\">\n          <strong>Presenter:<\/strong> Fiona Simpkins, M.D.<\/li>\n<li style=\"text-align:justify\">\n          <strong>Session: <\/strong>Scientific Plenary II: Hitting the Target &#8211; Maximizing IMPACT<\/li>\n<li style=\"text-align:justify\">\n          <strong>Date\/Time:<\/strong> Saturday, March 15, 8:25am PST<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Poster Presentation<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Abstract Title:<\/strong> The WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Effects With Microtubule Inhibitor\u2013Based Antibody Drug Conjugates (ADCs) in Preclinical Models<\/li>\n<li style=\"text-align:justify\">\n          <strong>Presenter:<\/strong> Joanna Guo, Ph.D.<\/li>\n<li style=\"text-align:justify\">\n          <strong>Session:<\/strong> In-Person Poster Session<\/li>\n<li style=\"text-align:justify\">\n          <strong>Date and Time:<\/strong> Sunday, March 16, 8:15-8:45am and 2:10-3:00pm PST<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About Zentalis Pharmaceuticals\u00a0<\/strong>\u00a0<br \/>Zentalis<sup>\u00ae<\/sup> Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.\u00a0<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lFjST4HpmKeZETFUQQpNzNNf0BPY9RSwJSJbq1kuXTkFjWCxdfrtgIduL2KgxR0srdI8nJiW3eKOSWn1f4eKqCTcySTZc7pTIYabJMuf3Kk=\" rel=\"nofollow\" target=\"_blank\">www.zentalis.com<\/a>. Follow Zentalis on X\/Twitter at @<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=juhk-X9k7i9cuCEsqVZ1n2J6HhNKvXLOokyqVg7EukCJiG0pBcUgmkQ_2UBsXuoLmheRD6oI3yzQRwpiKFJUQeqB7SZyO1eZiPxq8pyuiK-YSctsTPOzzt3DWRdEvuQ4\" rel=\"nofollow\" target=\"_blank\">ZentalisP<\/a> and on LinkedIn at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xYBc1uY73czajWPyMEGlYNOCqcVKrIzA2q6LQ5uNT-dUVMvjTgNVJ6DkH2-SaAbLD_8JpCIDNDQcWX2uolJADwfX7rZrHgH9LjRhUUUrNDcgs9MnLGIWn_7aXbdnwl9N523JJdnjbBfjjM4eRVCrNOZRXkahKIy7u6WJsGyTNB7nJIcuPS60S5h_h_DSr3Lb\" rel=\"nofollow\" target=\"_blank\">www.linkedin.com\/company\/zentalis-pharmaceuticals<\/a>.\u00a0<\/p>\n<p>\n        <strong>Contact:<\/strong>\u00a0<br \/>Haibo Wang\u00a0&#8211; Chief Business Officer<br \/>Ron Moldaver &#8211; Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WrbrkLwPtz-8NFtPW1nqivAERuccr9XTQUJfOYOJ7p5zHy4bWauEOy26Vb81eRGvC8ZHPid6CZ4MX5FqbzjwxA==\" rel=\"nofollow\" target=\"_blank\">ir@zentalis.com<\/a> \u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmVjYjJiMGMtZmUxOS00MmVjLThlMmEtZDkwNTNmOTlmNGFmLTEyMDYyOTY=\/tiny\/ZENTALIS-PHARMACEUTICALS.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) &#8212; Zentalis\u00ae Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women\u2019s Cancer, to be held on March 14-17 in Seattle, Washington. Oral Presentation Abstract Title: Cyclin E1 is a Predictive &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-820502","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) &#8212; Zentalis\u00ae Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women\u2019s Cancer, to be held on March 14-17 in Seattle, Washington. Oral Presentation Abstract Title: Cyclin E1 is a Predictive &hellip; Continue reading &quot;Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T13:35:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer\",\"datePublished\":\"2025-03-03T13:35:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/\"},\"wordCount\":359,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/\",\"name\":\"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=\",\"datePublished\":\"2025-03-03T13:35:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer - Market Newsdesk","og_description":"Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) &#8212; Zentalis\u00ae Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women\u2019s Cancer, to be held on March 14-17 in Seattle, Washington. Oral Presentation Abstract Title: Cyclin E1 is a Predictive &hellip; Continue reading \"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-03T13:35:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer","datePublished":"2025-03-03T13:35:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/"},"wordCount":359,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/","name":"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=","datePublished":"2025-03-03T13:35:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzM5OSM2Nzg1NjA5IzIxOTQ3NDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-announces-multiple-data-presentations-at-society-of-gynecologic-oncology-2025-annual-meeting-on-womens-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women\u2019s Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=820502"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820502\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=820502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=820502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=820502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}